In Japan, a satisfied patient and an unmet need are often the same person.
“Are you satisfied with your current treatment?”
The patient says yes. A few questions later, it’s clear that the yes was doing a lot of work. The weekly hospital trips wear her down. Prepping the daily dose has become something she resents. She’s stopped going to her son’s school events because the treatment schedule never lines up with them.
By her own account, she’s satisfied. She also has a long list of needs that nobody is meeting.
We see this constantly. After years of in-depth interviews with patients and physicians across rare, chronic, cardiovascular and neurological conditions, one pattern keeps returning: in Japan, dissatisfaction almost never announces itself. Patients don’t complain. That isn’t the same as having no problem, and the strategies that mistake the first thing for the second tend to be the ones that stall here.
There’s a plainer way to put it. In Japan, what a patient tells you doesn’t reveal the structure behind what the patient decides.
Why do Unsatisfied Patients Say They're Satisfied
A survey collapses all of this into one cheerful number. But the contradiction isn’t random, and it doesn’t start in the clinic.
Most Japanese patients haven’t accepted their treatment because it’s the best option available. They’ve accepted it because changing would be the risky move, and staying put feels safe.
It helps to leave healthcare aside for a moment. Caution about changing the status quo runs through Japanese life well beyond medicine. Money is the obvious example. Japanese households keep more than half of their financial assets in cash and deposits, far more than households in the US or Western Europe, where stocks and funds take a much bigger share. “I don’t need it to grow, I just don’t want it to lose value” is a financial attitude, but you can hear the same instinct in how people shop: sticking with brands they’ve used for years, moving slowly to new services, leaning on “well, everybody uses it” as a reason to buy.
Medicine is where this caution bites hardest, because medicine is where being wrong costs the most. Change your treatment, get worse, and you may not be able to undo it. That fear keeps patients anchored to whatever they’re already doing.
So she says she’s satisfied. Not because the treatment has won her over, but because the familiar option feels safer than the unknown one. The lines we hear over and over in interviews (“it’s a hassle, but I’ve done it for years and I’m used to it,” or “I’d be happy if it were easier, but I’m not struggling”) aren’t the words of a patient who’s checked out. They’re a sensible, risk-averse read of the situation. The treatment she’s on has a track record with her, and the alternatives don’t.
Something cultural sits underneath that. Adapting to the circumstances you’re handed has long been treated in Japan as a strength, so dissatisfaction gets sorted into the “get used to it” pile rather than the “go change it” pile. The patient can describe the problem perfectly well. She just doesn’t see why she would need to.
All of which means the usual reading of a satisfaction score, high number therefore no problem, falls apart in Japan. Underneath that number is a layer of burden and unmet need the patient hasn’t fully admitted even to herself.
The "Autonomous Patient" Doesn't Exist in Japan
A lot of Western healthcare marketing runs on one assumption: inform patients and they’ll go looking for something better. In plenty of markets that holds. In Japan it barely turns over.
There’s no shortage of Japanese patients who know about newer therapies. They read about them online; they hear about them through patient groups. Information isn’t the gap. The gap is that hardly any of them will take what they’ve learned to their doctor and ask to switch.
However good a new therapy looks on paper, to the patient it’s an unknown. The side effects, whether it suits her body, whether it’ll upend her daily routine, none of that is settled. Set all of it against years of knowing exactly what to expect from her current regimen, and most patients here stay where they are. They want to feel better. They simply count the act of changing as a cost in its own right.
The Doctor is the Way Out
So how does a Japanese patient ever break out of that holding pattern? Through the doctor she trusts.
Two structural things set this up. Japan’s universal insurance, along with programs like the high-cost medical expense benefit, means money is rarely the single biggest factor in a treatment decision. In much of the West, wrangling with insurers pushes patients into the role of active negotiator. In Japan that pressure mostly isn’t there.
Trust in experts also runs high, and nowhere higher than in the long relationship a patient has with her attending physician. That doctor isn’t just the person who signs the prescriptions. They’ve watched over her health for five years, ten, sometimes twenty or more.
What comes out of that is a particular way of deciding. Less “I’ll pick the best treatment myself,” more “I’ll decide with the doctor I trust.” And the logic holds up. Decide on your own and you carry the outcome alone. Go with your physician’s recommendation and the decision rests on an expert you believe in. The risk hasn’t gone anywhere, but where it sits in your head has moved. It’s a rational way of handling uncertainty, not a sign of dependence.
Why Second Opinions Don't Travel
The same setup explains why second opinions, so ordinary in the West, barely happen in Japan.
In Western systems a doctor is partly a service provider, and comparing several opinions reads as the smart thing to do. In Japan, asking a physician you’ve seen for years for a second opinion can land as something else entirely, a signal that you don’t trust them. Patients don’t put it to themselves in those terms, but they steer clear of anything that might damage a relationship they’ve spent years building. A new doctor is, once again, an unknown to be avoided. Any plan that assumes patients will act the moment you put options in front of them has misjudged the market.
What This Means for Entering and Growing in Japan
Lay all of that out and the shape of a workable strategy starts to come through.
Begin with what patient research is actually for. It isn’t a way to move patients directly. Its job is to surface the complaints they never voice, the resignation folded into their daily routine, the needs they’ve never named, so you can work out what doctors should be saying to patients and how. The research builds the foundation. It isn’t the lever you pull.
The lever is the physician. A patient thinking a new therapy sounds good doesn’t, on its own, outweigh the risk of switching. What counts for more is getting the attending physician to understand the therapy well enough to recommend it without hesitation, because that recommendation is what gives the patient solid ground to take the risk.
Status-quo bias has to be built into the plan from the start rather than bolted on later. Getting a Japanese patient onto a new treatment takes a trusted doctor walking them through benefits that genuinely outweigh the cost of changing. Product-superiority messaging won’t crack “I’m fine as I am.” A recommendation from a physician who understands the patient’s life might.
Japanese patients are passive by default, so patient education on its own won’t shift prescribing.
Our Read
The reflex to put the patient at the center, inform them, hand them the choice, expect them to push for better care, is wired so deeply into Western healthcare marketing that it tends to get exported without a second thought. In Japan it misfires, and the satisfaction score is a good place to watch it happen.
The shift worth making is this. In Japan the unit of decision isn’t the patient; it’s the relationship between patient and physician. A patient’s “satisfaction” is often a measure of how safe the current situation feels, not of how well her needs are being met, and the road to change runs through her doctor rather than around them.
For a foreign pharma or medtech brand, that points to two jobs. Use patient research to understand the silence, not to mobilize the patient out of it. And put real investment into the physician, because they’re the only one who can turn a new therapy from an unknown risk into something a Japanese patient feels safe accepting.
Take the satisfaction number at face value and you’ll build for a patient who was never going to switch. Treat it as a question, what isn’t this person telling me, and who do they trust enough to hear it from, and you’re building for the market you’ve actually got.
*CarterJMRN conducts in-depth patient and healthcare-professional research across rare, chronic, cardiovascular and neurological disease areas in Japan. If you’d like to talk about patient insight or market-entry strategy for the Japanese healthcare market, get in touch.*
About CarterJMRN
CarterJMRN is a Japan-based market research agency specialising in qualitative and immersive methodologies that are tailored to the question at hand. Whether you are a global brand exploring Japan market entry, an established operator navigating category disruption, or a regional challenger building a new competitive strategy, CarterJMRN brings a wide portfolio of methodologies and more than thirty years of Japan market expertise to your brief.
Our qualitative toolkit spans from in-depth interviews and focus groups to in-situ ethnography and digital ethnography, allowing us to move fluidly between methods and combine them where needed to unlock deeper understanding. We apply this methodological breadth across a wide range of categories, including food and beverage, dining out, personal care, luxury, and AgeTech, where the nature of the question often demands different levels of immersion, sensitivity, and contextual depth.
Want to go deeper? Look at our case studies and other blog articles:
‘An Immersive Safari into the Life of Older Adults in Rural Areas’
‘Exploring Usability and User Experience of an Autonomous Driving System’